Aarti Drugs announced an interim dividend of ₹2 per equity share (20%) for the financial year 2025-26. The record date for the dividend is set for February 9, 2026. In addition, the Board approved the inclusion of functional heads in the list of Senior Management Personnel, effective February 3, 2026, reflecting organizational alignment.
Interim Dividend Declared
The Board of Directors has approved an interim dividend of ₹2 per equity share, which is 20% on a face value of ₹10. This dividend is applicable for the financial year 2025-26. The total dividend payout will amount to ₹18,25,40,000.
Important Dates
The record date to determine shareholders eligible for the interim dividend is February 9, 2026.
Senior Management Appointments
Several key functional heads have been included in the list of Senior Management Personnel, effective February 3, 2026, further aligning roles within the company:
- Shri Arun M. Patil, Vice President – Marketing
- Shri Digvir Jadeja, Vice President – Export Marketing
- Shri Jatin Chheda, Manager – Purchase
Financial Performance: Q3 2026
Aarti Drugs’ Q3 2026 standalone revenue from operations reached ₹52,880 lakhs with total income reported at ₹53,002 lakhs. The company’s profit after tax stood at ₹3,384 lakhs. Basic and diluted EPS was ₹3.71. For the nine months ended December 31, 2025, the standalone revenue from operations totalled ₹1,62,871 lakhs with profit after tax reported at ₹12,426 lakhs, with earnings per share of ₹13.61.
Consolidated Results
Consolidated revenue from operations for Q3 2026 was ₹60,171 lakhs with a total income of ₹60,294 lakhs. The profit after tax reached ₹4,055 lakhs. Earnings per share was ₹4.44. For the nine months ended December 31, 2025, consolidated revenue from operations was ₹1,84,501 lakhs, with the profit after tax at ₹13,968 lakhs, and earnings per share reported at ₹15.30.
Source: BSE
